GlassScriptPhysician profile
Chhavi Agarwal
NPI 1053407700
$3,618.14
in general payments reported to CMS, 2019-2025
23 companies · $780 in 2025
The $780 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $198 · 2021: $537 · 2022: $602 · 2023: $624 · 2024: $768 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,172.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $910.79 | 2019-2025 | Lupron Depot, Botox |
| Azurity Pharmaceuticals, INC. | $411.76 | 2023-2025 | Triptodur, Triptodur |
| Arbor Pharmaceuticals, INC. | $347.99 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $309.06 | 2022-2025 | Unithroid |
| Ascendis Pharma Endocrinology INC | $304.45 | 2022-2025 | Skytrofa |
| Pfizer INC. | $254.53 | 2022-2025 | |
| Tolmar, INC. | $243.43 | 2023-2025 | Fensolvi |
| Alexion Pharmaceuticals, INC. | $174.44 | 2019-2025 | Strensiq |
| Novo Nordisk INC | $130.48 | 2023-2025 | Sogroya, Wegovy |
| Endo USA, INC. | $98.15 | 2024-2025 | Supprelin |
| Endo Pharmaceuticals INC. | $89.37 | 2019-2024 | Supprelin |
| Sandoz INC. | $66.40 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $60.07 | 2024-2025 | |
| Eton Pharmaceuticals, INC. | $35.78 | 2023 | Alkindi |
| Tolmar Pharmaceuticals, INC. | $31.30 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $22.44 | 2021 | |
| Chiesi USA, INC. | $22.05 | 2025 | Myalept |
| Ultragenyx Pharmaceutical INC. | $21.88 | 2021 | |
| Biomarin Pharmaceutical INC. | $20.51 | 2023 | Voxzogo 1.2mg |
| Sanofi-Aventis U.S. LLC | $19.11 | 2024 | |
| Ibsa Pharma INC. | $17.68 | 2021 | |
| Medtronic, INC. | $13.46 | 2022 | |
| Acadia Pharmaceuticals INC | $13.01 | 2023 | Daybue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chhavi Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.